13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001782539
Total reported value
$131.5M
$131.5M
24 檔
22.7%
At the close of Q3 2025, Nan Fung Group Holdings Ltd disclosed equity holdings valued at approximately $131.5M, spread across 24 reported holdings.
In Q3 2025, Nan Fung Group Holdings Ltd adopted a defensive or profit-taking posture, trimming 3 positions and completely liquidating 18 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | OCS | Oculis Holding AG | Stock-Other | 15.18% | -4.52% | — | |
| 2 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 9.13% | -0.13% | — | |
| 3 | ONC | Beone Medicines Ltd-adr | Stock-Other | 8.99% | -0.44% | — | |
| 4 | INCY | Incyte CORP | Stock-Healthcare | 8.40% | +0.46% | — | |
| 5 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 8.32% | +0.63% | — | |
| 6 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 7.95% | +2.75% | — | |
| 7 | JOBY | Joby Aviation, Inc. | Stock-Industrials | 5.88% | — | — | |
| 8 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 4.87% | +0.15% | -10.43% | |
| 9 | ASND | Ascendis Pharma A/S | Stock-Other | 4.54% | -2.57% | EXIT | |
| 10 | LAB | Standard Biotools Inc | Stock-Other | 4.11% | — | — | |
| 11 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 3.69% | +0.09% | — | |
| 12 | ARGX | Argenx Se - Adr | Stock-Healthcare | 3.46% | +0.29% | — | |
| 13 | KYMR | Kymera Therapeutics Inc | Stock-Other | 2.93% | +0.57% | — | |
| 14 | ETHA | Ishares Ethereum Trust ETF | ETF-Other | 2.67% | -0.20% | — | |
| 15 | RKLB | Rocket Lab CORP | Stock-Industrials | 2.37% | — | — | |
| 16 | IBIT | Ishares Bitcoin Trust ETF | ETF-Crypto | 1.74% | -0.11% | — | |
| 17 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.51% | +1.20% | — | |
| 18 | HRMY | Harmony Biosciences Holdings | Stock-Other | 1.25% | +0.13% | -92.66% | |
| 19 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.90% | — | — | |
| 20 | BOLT | Bolt Biotherapeutics Inc | Stock-Other | 0.52% | -0.09% | — | |
| 21 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.48% | -0.24% | — | |
| 22 | REPL | Replimune Group Inc | Stock-Other | 0.45% | — | — | |
| 23 | RANI | Rani Therapeutics Holdings-a | Stock-Other | 0.41% | -0.01% | — | |
| 24 | BSLK | Bolt Projects Holdings Inc | Stock-Other | 0.26% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | OCS | Oculis Holding AG | +7.2% | — | Unchanged |
| 2 | RYTM | Rhythm Pharmaceuticals Inc | +6.2% | — | Unchanged |
| 3 | MDGL | Madrigal Pharmaceuticals Inc | +5.9% | — | Unchanged |
| 4 | ONC | Beone Medicines Ltd-adr | +5.5% | — | Unchanged |
| 5 | INCY | Incyte CORP | +5.5% | — | Unchanged |
| 6 | ASND | Ascendis Pharma A/S | +2.8% | — | Unchanged |
| 7 | LAB | Standard Biotools Inc | +2.5% | — | Unchanged |
| 8 | ACAD | Acadia Pharmaceuticals Inc | +2.3% | — | Unchanged |
| 9 | KYMR | Kymera Therapeutics Inc | +2.2% | — | Unchanged |
| 10 | ARGX | Argenx Se - Adr | +2.1% | — | Unchanged |
| 11 | RXRX | Recursion Pharmaceuticals-a | +2% | -10.43% | Trim |
| 12 | RVMD | Revolution Medicines Inc | +1% | — | Unchanged |
| 13 | BCYC | Bicycle Therapeutics Plc-adr | +0.4% | — | Unchanged |
| 14 | TRDA | Entrada Therapeutics Inc | +0.1% | — | Unchanged |
| 15 | RANI | Rani Therapeutics Holdings-a | -0.1% | — | Unchanged |
| 16 | REPL | Replimune Group Inc | -2.8% | — | Trim |
| 17 | HRMY | Harmony Biosciences Holdings | -8.7% | -92.66% | Trim |
| 18 | ILMN | Illumina Inc | — | EXIT | Sold out |
| 19 | VRNA | Verona Pharma PLC - Adr | — | EXIT | Sold out |
| 20 | ZLAB | Zai Lab Ltd-adr | — | EXIT | Sold out |
| 21 | MIRM | Mirum Pharmaceuticals Inc | — | EXIT | Sold out |
| 22 | PTGX | Protagonist Therapeutics Inc | — | EXIT | Sold out |
| 23 | SLNOEUR | Soleno Therapeutics Inc | — | EXIT | Sold out |
| 24 | XENE | Xenon Pharmaceuticals Inc | — | EXIT | Sold out |
| 25 | ✓ | Merus N V | — | EXIT | Sold out |
| 26 | LBRX | Lb Pharmaceuticals Inc | — | NEW | New buy |
| 27 | JOBY | Joby Aviation, Inc. | — | NEW | New buy |
| 28 | TRML | Tourmaline Bio Inc | — | EXIT | Sold out |
| 29 | EXEL | Exelixis Inc | — | EXIT | Sold out |
| 30 | GERN | Geron CORP | — | EXIT | Sold out |
| 31 | 4XC1 | Kalvista Pharmaceuticals Inc | — | EXIT | Sold out |
| 32 | ETHA | Ishares Ethereum Trust ETF | — | NEW | New buy |
| 33 | RKLB | Rocket Lab CORP | — | NEW | New buy |
| 34 | IBIT | Ishares Bitcoin Trust ETF | — | NEW | New buy |
| 35 | CLYM | Climb Bio Inc | — | EXIT | Sold out |
| 36 | BOLT1EUR | Bolt Biotherapeutics Inc | — | EXIT | Sold out |
| 37 | BOLT | Bolt Biotherapeutics Inc | — | NEW | New buy |
| 38 | DBVT | Dbv Technologies Sa-spon Adr | — | EXIT | Sold out |
| 39 | ✓ | Bolt Projs Hldgs Inc | — | EXIT | Sold out |
| 40 | BSLK | Bolt Projects Holdings Inc | — | NEW | New buy |
| 41 | ✓ | Affimed N V | — | EXIT | Sold out |
| 42 | ALXO | Alx Oncology Holdings Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Nan Fung Group Holdings Ltd reported a total U.S. public equity portfolio value of $131.5M across 24 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including OCS, MDGL, ONC) accounted for 22.7% of total reported equity market value during Q3 2025.
Top New Position Initiated
LBRX
市值: $4.7M
Top Position Liquidated / Trimmed
ILMN
前期市值: $9.5M
During Q3 2025, Nan Fung Group Holdings Ltd's top holdings by market value included OCS (15.2%)、MDGL (9.1%)、ONC (9.0%). The largest single position, OCS, represented 15.2% of total portfolio value.
In Q3 2025, Nan Fung Group Holdings Ltd made 28 total portfolio adjustments, initiating 7 new buys, adding to 0 positions, trimming 3 holdings, and fully liquidating 18 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.